- Home
- SAFT vs EYPT Comparison
SAFT vs EYPT Comparison
Compare SAFT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAFT | EYPT |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.3B |
| IPO Year | 2002 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SAFT | EYPT |
|---|---|---|
| Price | $73.84 | $14.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 112.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ 40.17 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,263,732,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $67.04 | $8.96 |
| 52 Week High | $81.49 | $19.11 |
Technical Indicators
Market Signals| Indicator | SAFT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 63.99 |
| Support Level | $71.13 | $14.50 |
| Resistance Level | $75.27 | $14.82 |
| Average True Range (ATR) | 1.38 | 0.78 |
| MACD | 0.41 | 0.28 |
| Stochastic Oscillator | 96.49 | 89.96 |
Price Performance
Historical ComparisonAbout SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.